- Home
- ORIC vs PEB Comparison
ORIC vs PEB Comparison
Compare ORIC & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- PEB
- Stock Information
- Founded
- ORIC 2014
- PEB 2009
- Country
- ORIC United States
- PEB United States
- Employees
- ORIC N/A
- PEB N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- ORIC Health Care
- PEB Real Estate
- Exchange
- ORIC Nasdaq
- PEB Nasdaq
- Market Cap
- ORIC 1.1B
- PEB 1.2B
- IPO Year
- ORIC 2020
- PEB 2009
- Fundamental
- Price
- ORIC $11.54
- PEB $11.06
- Analyst Decision
- ORIC Strong Buy
- PEB Hold
- Analyst Count
- ORIC 11
- PEB 8
- Target Price
- ORIC $18.78
- PEB $12.19
- AVG Volume (30 Days)
- ORIC 1.1M
- PEB 1.9M
- Earning Date
- ORIC 11-13-2025
- PEB 11-05-2025
- Dividend Yield
- ORIC N/A
- PEB 0.38%
- EPS Growth
- ORIC N/A
- PEB N/A
- EPS
- ORIC N/A
- PEB N/A
- Revenue
- ORIC N/A
- PEB $1,464,126,000.00
- Revenue This Year
- ORIC N/A
- PEB $2.25
- Revenue Next Year
- ORIC N/A
- PEB $2.96
- P/E Ratio
- ORIC N/A
- PEB N/A
- Revenue Growth
- ORIC N/A
- PEB 0.99
- 52 Week Low
- ORIC $3.90
- PEB $7.42
- 52 Week High
- ORIC $14.93
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- ORIC 40.39
- PEB 52.99
- Support Level
- ORIC $11.28
- PEB $10.46
- Resistance Level
- ORIC $12.50
- PEB $11.63
- Average True Range (ATR)
- ORIC 0.82
- PEB 0.44
- MACD
- ORIC -0.16
- PEB -0.01
- Stochastic Oscillator
- ORIC 22.22
- PEB 62.50
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.